Key terms
About ZNTL
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in New York, NY.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest ZNTL news
Today
1:19am ET
Assessing Zentalis Pharmaceuticals: A Balanced Hold Rating Amidst Financial Stability and Uncertain Market Prospects
Yesterday
5:21am ET
Analysts Offer Insights on Healthcare Companies: Teva Pharmaceutical (TEVA), Zentalis Pharmaceuticals (ZNTL) and Paragon 28 (FNA)
Yesterday
5:20am ET
Buy Rating on Zentalis Pharmaceuticals Amid High Expectations for Azeno Drug Trials
May 08
10:09pm ET
Stifel Nicolaus Remains a Buy on Zentalis Pharmaceuticals (ZNTL)
May 08
6:13am ET
Zentalis price target lowered to $40 from $46 at H.C. Wainwright
Apr 09
4:43pm ET
Zentalis Pharmaceuticals to Present at Upcoming Conferences
Apr 01
7:59am ET
Immunome price target raised to $33 from $27 at Wedbush
Mar 01
1:04am ET
Zentalis Pharmaceuticals: A Cautious Hold Amidst Speculative Opportunities and Upcoming Clinical Updates
Feb 29
5:19pm ET
Zentalis files automatic mixed securities shelf
Feb 28
8:48am ET
Zentalis price target raised to $15 from $12 at Wedbush
Feb 28
7:47am ET
Oppenheimer Keeps Their Buy Rating on Zentalis Pharmaceuticals (ZNTL)
Feb 28
6:38am ET
Buy Rating Affirmed for Zentalis Pharmaceuticals on Strategic Positioning and Clinical Prospects in Ovarian Cancer Treatment
Feb 28
5:43am ET
Buy Rating on Zentalis Pharmaceuticals Amidst Undervalued Share Price and Promising Clinical Developments
Feb 27
1:25pm ET
TD Cowen Keeps Their Buy Rating on Zentalis Pharmaceuticals (ZNTL)
Feb 27
7:06am ET
Zentalis sees cash runway into 2026
Feb 27
7:05am ET
Zentalis announces anticipated upcoming milestones
Feb 27
7:03am ET
Zentalis reports 2023 EPS ($4.47), consensus ($4.54)
Feb 15
4:22pm ET
Zentalis Pharmaceuticals Updates Bylaws for Enhanced Governance
ZNTL Financials
Key terms
Ad Feedback
ZNTL Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
ZNTL Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range